O'Brien Patrick's Form 4 filing
Arrowhead Pharmaceuticals, Inc. (ARWR) · filed Jan 7, 2022
- Accession no.
- 0001209191-22-002599
- Filed
- Jan 7, 2022
- Trade date
- Dec 4, 2020-Jan 5, 2022
- Filing delay
- 399 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 0 derivative transactions. Open-market sales total $2.01M. It was filed 399 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| O'Brien PatrickCIK 0001627183 | Officer (General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 5, 2022 | Common Stock | SSaleDisposed | −12,434 | $60.49 | −$752,132.66 | 368,941 | Direct | |
| Jan 5, 2022 | Common Stock | SSaleDisposed | −10,350 | $61.88 | −$640,458 | 358,591 | Direct | |
| Jan 5, 2022 | Common Stock | SSaleDisposed | −5,000 | $62.49 | −$312,450 | 353,591 | Direct | |
| Jan 5, 2022 | Common Stock | SSaleDisposed | −4,400 | $63.75 | −$280,500 | 349,191 | Direct | |
| Jan 5, 2022 | Common Stock | SSaleDisposed | −316 | $64.35 | −$20,334.6 | 348,875 | Direct | |
| Dec 4, 2020 | Common Stock | GGiftDisposed | −800 | $0.00 | $0 | 348,075 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.